Imidacloprid/Permethrin/Pyriproxyfen

Verify with FDA CVM →

15 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
15
Total Reports
3
Deaths Reported
2000.0%
Death Rate

Active Ingredients

Imidacloprid/Permethrin/Pyriproxyfen

Administration Routes

TopicalUnknown

Species Affected

Dog 15

Most Affected Breeds

Shih Tzu 2
Siberian Husky 1
Dachshund (unspecified) 1
Pinscher - Miniature 1
Retriever - Labrador 1
Rottweiler 1
Terrier (unspecified) 1
Greyhound - Italian 1
Spitz - German Pomeranian 1
Dachshund - Miniature 1

Most Reported Reactions

Vomiting 5
Lethargy (see also Central nervous system depression in 'Neurological') 4
Lack of efficacy (ectoparasite) - flea 4
Inappropriate defecation 3
Vocalisation 2
Anorexia 2
Abdominal pain 2
Death 2
Other abnormal test result NOS 2
Diarrhoea 2
Loose stool 2
Inappropriate urination 2

Outcome Breakdown

Outcome Unknown
5 (33.3%)
Recovered/Normal
5 (33.3%)
Died
2 (13.3%)
Ongoing
2 (13.3%)
Euthanized
1 (6.7%)

Data Summary

Metric Value
Total adverse event reports 15
Reports involving death 3
Case-fatality rate (reported events) 2000.0%
Distinct species in reports 1
Distinct breeds in reports 14
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Imidacloprid/Permethrin/Pyriproxyfen Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 15 adverse event reports referencing Imidacloprid/Permethrin/Pyriproxyfen, including 3 reports in which the animal died — a 2000.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Imidacloprid/Permethrin/Pyriproxyfen. Reported administration routes include Topical, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Imidacloprid/Permethrin/Pyriproxyfen reports are Dog (15 reports), with Dog accounting for the largest share. Within those species, Shih Tzu (2), Siberian Husky (1), Dachshund (unspecified) (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Imidacloprid/Permethrin/Pyriproxyfen are Vomiting (5), Lethargy (see also Central nervous system depression in 'Neurological') (4), Lack of efficacy (ectoparasite) - flea (4), Inappropriate defecation (3). Of the 15 reports with a coded outcome, Outcome Unknown is the leading category at 33.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Imidacloprid/Permethrin/Pyriproxyfen.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial